Outcomes of Periosteal-Iliac Bone Autografting with Platelet-Rich Plasma in Patients with Hepple V Talar Lesions: A Retrospective Study

采用富血小板血浆进行骨膜-髂骨自体移植治疗Hepple V型距骨损伤患者的疗效:一项回顾性研究

阅读:1

Abstract

BACKGROUND Talus osteochondral injury is a common and often chronic condition characterized by pain in the ankle joint. This retrospective study aimed to evaluate outcomes from periosteal-iliac bone autografting combined with intra-articular platelet-rich plasma (PRP) in treatment for Hepple V osteochondral lesions of the talus. MATERIAL AND METHODS The clinical data of 63 patients with Hepple type V talar osteochondral lesions who underwent periosteum-iliac bone autograft in our hospital were retrospectively analyzed. The patients were divided into a control group (n=33) and observation group (PRP, n=30) based on whether intra-articular PRP injection was performed during surgery. Visual analog scale scores for pain, SF-36 quality of life scale scores, range of motion of the joint, and occurrence of complications were evaluated. Functional recovery was evaluated using the American Orthopedic Foot and Ankle Society (AOFAS) scoring system. RESULTS No soft tissue complications, including wound infection or skin necrosis, occurred in any of the patients after surgery. The observation group had significantly better range of motion, visual analog scale pain scores at rest, walking, and running, and SF-36 quality of life scores than the control group (all P<0.05). The AOFAS score of the observation group was slightly better than that of the control group, although there was no statistically significant difference (91.2 vs 88.6, P=0.12). CONCLUSIONS For Hepple V osteochondral lesions of the talus, periosteum-iliac bone autografting combined with intra-articular PRP can repair cartilage defects, relieve pain, and improve joint function, demonstrating it is a safe and effective alternative.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。